Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. Chief Legal Officer and Secretary Jill Andersen reported a mix of stock activity involving restricted stock units (RSUs) and common shares. On February 15, RSUs covering 165,000 shares converted into common stock at a stated price of $0.0000 per share, reflecting an RSU vesting event. The RSU award vests over an eighteen-month period, with one-third vesting every six months following the February 15, 2025 grant date, conditioned on continued service.
To cover tax withholding from this vesting, Andersen executed non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan adopted on February 20, 2025, selling 32,771 shares on February 17 at a weighted average price of $1.5396 and 34,939 shares on February 18 at a weighted average price of $1.5778. After these transactions, she directly held 181,736 shares of common stock, with an additional 500 shares held indirectly by her spouse.
Invivyd shareholder plans to sell common stock under Rule 144. The notice covers the proposed sale of 39,600 shares of common stock through Morgan Stanley Smith Barney LLC on or after 02/17/2026 on the Nasdaq market, with an aggregate market value of $61,776.00 at the time of filing.
The seller previously acquired 99,000 shares of Invivyd common stock on 02/15/2026 upon vesting of restricted stock units granted under the issuer’s 2021 Equity Incentive Plan as equity compensation. Invivyd had 281,987,033 shares of common stock outstanding when this notice was prepared.
IVVD received a Rule 144 notice for a planned sale of 36,630 shares of its common stock through Morgan Stanley Smith Barney on the Nasdaq, with an aggregate market value of $57,142.80 and an approximate sale date of February 17, 2026.
The seller acquired 99,000 common shares on February 15, 2026 upon vesting of restricted stock units granted under the issuer’s 2021 Equity Incentive Plan as equity compensation. The filing states the seller represents not knowing any undisclosed material adverse information about the issuer.
Invivyd, Inc. filed a Form 144 notice for a planned sale of 39,600 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on Nasdaq, with an aggregate market value of $61,776.00 and 281,987,033 common shares outstanding noted in the form.
The seller acquired 99,000 common shares on 02/15/2026 upon vesting of restricted stock units granted under the issuer’s 2021 Equity Incentive Plan, classified as equity compensation. The form also confirms the seller represents not knowing any undisclosed material adverse information about Invivyd.
A shareholder of Invivyd (symbol IVVD) has filed a notice of proposed sale of 39,600 shares of common stock, with an aggregate market value of 61,776.00, through Morgan Stanley Smith Barney on or about 02/17/2026 on Nasdaq.
The seller acquired 99,000 common shares on 02/15/2026 upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan as equity compensation. Invivyd had 281,987,033 shares outstanding when this notice was prepared.
Invivyd Inc. filed a Form 144 notice for a planned resale of 66,000 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq, with an aggregate market value of $102,960.00 based on the filing.
The securities relate to common stock acquired on 02/15/2026 upon vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan as equity compensation. The company reported 281,987,033 common shares outstanding in the same class at the time referenced in the notice.
Invivyd, Inc. received an updated ownership report from RA Capital Management, L.P., its RA Capital Healthcare Fund, and managers Peter Kolchinsky and Rajeev Shah. They report beneficial ownership of 28,857,208 shares of Invivyd common stock as of December 31, 2025, equal to 9.99% of the company.
The fund directly holds 17,119,096 common shares plus pre‑funded warrants exercisable for up to 21,342,442 additional shares, but a “Beneficial Ownership Blocker” in the warrants caps their ownership at 9.99%. The percentage is calculated using 233,122,834 shares outstanding as of October 30, 2025, 44,000,000 shares sold in November 2025, and 11,738,112 shares issuable upon warrant exercise. The reporting parties state the holdings are not for the purpose of changing or influencing control and include standard disclaimers about beneficial ownership status under Section 13(d).
Invivyd, Inc. received an updated ownership report showing that investment firms associated with Point72 and Steven A. Cohen beneficially own 16,653,036 shares of its common stock, representing 6.0% of the company as of December 31, 2025.
The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., while Point72 Capital Advisors, Inc. is its general partner and Mr. Cohen controls both entities. The reported percentage is based on 277,064,852 shares outstanding as of the completion of Invivyd’s underwritten public offering that closed on November 17, 2025. The reporting parties state the securities were not acquired to change or influence control of Invivyd.
Invivyd, Inc. received an updated ownership report from Biotechnology Value Fund and related entities, which together may be deemed to beneficially own 25,525,000 shares of Invivyd common stock, or approximately 9.0% of the company, as of December 31, 2025. This includes holdings of Pre-Funded Warrants exercisable for 6,000,000 shares at an exercise price of $0.0001 per share, subject to a 9.99% ownership blocker that limits exercises above that threshold. The group states the securities are not held for the purpose of changing or influencing control of Invivyd, outside of activities solely in connection with a nomination under relevant proxy rules.
Maverick Capital and related entities report a passive stake in Invivyd, Inc. (IVVD). As of December 31, 2025, Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively report beneficial ownership of 18,970,913 shares of Invivyd common stock, representing 6.7% of the outstanding shares, based on 281,987,033 shares reported by the company. The shares are held in client accounts of Maverick-managed funds, and the filers certify that the holdings were not acquired to change or influence control of Invivyd.